48 active
/
142 total (since 2015)
5
Phase 1 Active
17 total
12
Phase 2 Active
50 total
23
Phase 3 Active
56 total
9
Phase 4 Active
25 total
Top Sponsors (Industry)
Sorted by active Active Done Failed
UCB Biopharma SRL 6 7 0
AbbVie 4 5 1
Eli Lilly 3 3 0
Bristol-Myers Squibb 3 2 0
Takeda 3 1 0
Sun Pharmaceutical Industries Limited 2 3 0
Amgen 2 2 0
Novartis 1 10 0
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 1 1 0
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. 1 0 0
Spyre Therapeutics, Inc. 1 0 0
InventisBio Co., Ltd 1 0 0
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. 1 0 0
LAPIX Therapeutics Inc. 1 0 0
Telix Pharmaceuticals (Innovations) Pty Limited 1 0 0
NCT06668181 RECRUITING
An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
UCB Biopharma SRL n=40
NCT04009499 ACTIVE NOT RECRUITING
A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
UCB Biopharma SRL n=1,131
NCT06506916 RECRUITING
A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
UCB Biopharma SRL n=90
NCT04991116 RECRUITING
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
Sun Pharmaceutical Industries Limited n=650
NCT06100744 RECRUITING
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
AbbVie n=40
NCT06671496 RECRUITING
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
Takeda n=600
NCT06671483 RECRUITING
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
Takeda n=1,088
NCT06624228 ACTIVE NOT RECRUITING
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis
UCB Biopharma SRL n=684
NCT04804553 RECRUITING
Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis
Amgen n=60
NCT06588296 ACTIVE NOT RECRUITING
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
Eli Lilly and Company n=279
NCT06869551 RECRUITING
A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis
Bristol-Myers Squibb n=60
NCT04314531 ACTIVE NOT RECRUITING
Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)
Sun Pharmaceutical Industries Limited n=296
NCT07295509 NOT YET RECRUITING
A Study of Picankibart in Patients With Active Psoriatic Arthritis
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. n=222
NCT07286058 NOT YET RECRUITING
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
Takeda n=1,182
NCT05767047 RECRUITING
A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis
Amgen n=48
NCT04908202 ACTIVE NOT RECRUITING
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
Bristol-Myers Squibb n=670
NCT05669833 RECRUITING
Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
University of Pennsylvania n=63
NCT07052214 RECRUITING
PSMA PET Combined With MRI for the Detection of PCa
Telix Pharmaceuticals (Innovations) Pty Limited n=204
NCT03671148 ACTIVE NOT RECRUITING
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)
AbbVie n=444
NCT03675308 ACTIVE NOT RECRUITING
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
AbbVie n=964
NCT04908189 ACTIVE NOT RECRUITING
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment
Bristol-Myers Squibb n=729
NCT04527380 ACTIVE NOT RECRUITING
A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
Eli Lilly and Company n=101
NCT06640257 RECRUITING
A Study of the Efficacy and Safety of SHR-1314 for Adult Active Psoriatic Arthritis
Suzhou Suncadia Biopharmaceuticals Co., Ltd. n=200
NCT03410992 COMPLETED
A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
UCB Biopharma SRL n=435
NCT03896581 COMPLETED
A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
UCB Biopharma SRL n=400
NCT03370133 COMPLETED
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
UCB Biopharma SRL n=567
NCT03895203 COMPLETED
A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
UCB Biopharma SRL n=852
NCT04314544 COMPLETED
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)
Sun Pharmaceutical Industries Limited n=508
NCT04108468 COMPLETED
GOLimumab and Methotrexate Versus Methotrexate in Very Early PsA
The Leeds Teaching Hospitals NHS Trust n=84
NCT04632927 COMPLETED
Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNFα-Inhibitor Treatment
Novartis Pharmaceuticals n=119
NCT03769168 COMPLETED
An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)
Novartis Pharmaceuticals n=55
NCT03104400 COMPLETED
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)
AbbVie n=1,705
NCT03104374 COMPLETED
A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug
AbbVie n=642
NCT03598751 COMPLETED
Clinical Study of Efficacy and Safety of BCD-085 (Monoclonal Anti-IL-17 Antibody) in Psoriatic Arthritis
Biocad n=194
NCT04209205 COMPLETED
Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis
Novartis Pharmaceuticals n=381
NCT03103321 COMPLETED
Decision Aids in Improving Knowledge in Patients With Newly Diagnosed Prostate Cancer
Alliance for Clinical Trials in Oncology n=158
NCT03552276 COMPLETED
Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.
Sun Pharmaceutical Industries Limited n=281
NCT04711902 COMPLETED
Study of Efficacy and Safety of Secukinumab in Chinese Subjects With Active PsA Compared to Placebo.
Novartis Pharmaceuticals n=41
NCT03486457 COMPLETED
Efficacy And Safety Of Tofacitinib In Chinese Subjects With Active Psoriatic Arthritis
Pfizer n=204
NCT06084663 COMPLETED
Bioequivalence Study of Two Products of Apremilast 30 mg Tablets in Healthy, Adult, Human Subjects
Humanis Saglık Anonim Sirketi n=36
NCT04109976 COMPLETED
A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Active Psoriatic Arthritis
UCB Biopharma SRL n=214
NCT05046431 COMPLETED
Comparative Study of BAT2506 With Simponi® in Participants With Active Psoriatic Arthritis
Bio-Thera Solutions n=704
NCT02376790 COMPLETED
Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis
Amgen n=851
NCT03031782 COMPLETED
Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA)
Novartis Pharmaceuticals n=86
NCT04115748 TERMINATED
Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy
Gilead Sciences n=67
NCT04115839 TERMINATED
Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy
Gilead Sciences n=106
NCT03148860 COMPLETED
Impact of Concomitant MTX on Efficacy, Safety and Adherence of Ustekinumab-treatment in Patients With Active PsA
Dr. Frank Behrens n=186
NCT02673151 COMPLETED
68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment
Andrei Iagaru n=61
NCT02662985 COMPLETED
Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA)
Novartis Pharmaceuticals n=166
NCT02771210 COMPLETED
Study of Efficacy and Safety of Secukinumab in Psoriatic Arthritis and Axial Spondyloarthritis Patients With Active Enthesitis Including One Achilles Tendon Site
Novartis Pharmaceuticals n=204
NCT02745080 COMPLETED
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
Novartis Pharmaceuticals n=853
NCT02404350 COMPLETED
Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis
Novartis Pharmaceuticals n=997
NCT02584855 COMPLETED
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
Eli Lilly and Company n=394
NCT03357471 COMPLETED
Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease
UCB Biopharma S.P.R.L. n=70
NCT03736161 COMPLETED
Safety and Efficacy of Tofacitinib vs Methotrexate in the Treatment of Psoriatic Arthritis
Globe Pharmaceuticals Limited n=61
Data: ClinicalTrials.gov